Nothing Special   »   [go: up one dir, main page]

HK1105421A1 - Il-1 antagonist formulations il-1 - Google Patents

Il-1 antagonist formulations il-1

Info

Publication number
HK1105421A1
HK1105421A1 HK07110745.0A HK07110745A HK1105421A1 HK 1105421 A1 HK1105421 A1 HK 1105421A1 HK 07110745 A HK07110745 A HK 07110745A HK 1105421 A1 HK1105421 A1 HK 1105421A1
Authority
HK
Hong Kong
Prior art keywords
antagonist formulations
antagonist
formulations
Prior art date
Application number
HK07110745.0A
Other languages
English (en)
Inventor
Daniel Dix
Katherine Bowers
Goolcharran Chimanlall
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of HK1105421A1 publication Critical patent/HK1105421A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2006IL-1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/545IL-1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK07110745.0A 2004-08-17 2007-10-04 Il-1 antagonist formulations il-1 HK1105421A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60213704P 2004-08-17 2004-08-17
PCT/US2005/029428 WO2006023665A2 (en) 2004-08-17 2005-08-17 Il-1 antagonist formulations

Publications (1)

Publication Number Publication Date
HK1105421A1 true HK1105421A1 (en) 2008-02-15

Family

ID=35968186

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07110745.0A HK1105421A1 (en) 2004-08-17 2007-10-04 Il-1 antagonist formulations il-1

Country Status (15)

Country Link
US (1) US7365165B2 (xx)
EP (2) EP1778723B1 (xx)
JP (2) JP4948410B2 (xx)
CN (1) CN101014617B (xx)
AU (1) AU2005277357B2 (xx)
BR (1) BRPI0514411B8 (xx)
CA (1) CA2576519C (xx)
DK (1) DK1778723T3 (xx)
ES (1) ES2395035T3 (xx)
HK (1) HK1105421A1 (xx)
PL (1) PL1778723T3 (xx)
PT (1) PT1778723E (xx)
SI (1) SI1778723T1 (xx)
WO (1) WO2006023665A2 (xx)
ZA (1) ZA200701529B (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06001283A (es) 2003-08-05 2006-04-11 Novo Nordisk As Derivados de insulina novedosos.
ES2371361T3 (es) 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
CA2687246A1 (en) * 2007-06-01 2008-12-11 Acologix, Inc. High temperature stable peptide formulation
EP2167032B1 (en) 2007-06-13 2019-08-07 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US9492375B2 (en) * 2008-07-23 2016-11-15 Warsaw Orthopedic, Inc. Foam carrier for bone grafting
ES2607003T3 (es) 2008-10-30 2017-03-28 Novo Nordisk A/S Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria
EP3470421B9 (en) 2010-07-29 2023-10-04 Buzzard Pharmaceuticals AB Chimeric il-1 receptor type i antagonists
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー/エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
CA3076725A1 (en) 2011-11-18 2013-05-23 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles
ES2828656T3 (es) * 2012-04-04 2021-05-27 Polaris Group Composición que comprende arginina desiminasa pegilada
WO2014035361A1 (en) * 2012-08-26 2014-03-06 R-PHARM, CJSC (Closed Joint Stock Company) IL-1β INHIBITOR COMPOSITION AND USE THEREOF
US20140308239A1 (en) 2013-03-13 2014-10-16 Eleven Biotherapeutics, Inc. Chimeric cytokine formulations for ocular delivery
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー/エス 新規投与レジメン
WO2018050870A1 (en) 2016-09-16 2018-03-22 Leukocare Ag A novel method for stabilization of a biopharmaceutical drug product during processing
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000807A1 (en) * 1991-07-03 1993-01-21 Cryolife, Inc. Method for stabilization of biomaterials
JP3822383B2 (ja) * 1993-12-17 2006-09-20 持田製薬株式会社 可溶性トロンボモジュリン含有組成物
EP0820299B1 (en) * 1995-02-06 2002-04-24 Genetics Institute, Inc. Formulations for il-12
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
JP4172842B2 (ja) * 1997-05-02 2008-10-29 生化学工業株式会社 コンドロイチナーゼ組成物
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US20030113316A1 (en) * 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
DE10204792A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
WO2004062646A1 (en) * 2003-01-08 2004-07-29 Chiron Corporation Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants

Also Published As

Publication number Publication date
PL1778723T3 (pl) 2013-03-29
PT1778723E (pt) 2013-01-25
WO2006023665A3 (en) 2006-08-03
US20060040852A1 (en) 2006-02-23
AU2005277357A1 (en) 2006-03-02
ZA200701529B (en) 2008-09-25
EP2311871A2 (en) 2011-04-20
US7365165B2 (en) 2008-04-29
JP2008510716A (ja) 2008-04-10
JP4948410B2 (ja) 2012-06-06
CN101014617A (zh) 2007-08-08
SI1778723T1 (sl) 2013-02-28
BRPI0514411B8 (pt) 2021-05-25
BRPI0514411B1 (pt) 2020-09-15
BRPI0514411A (pt) 2008-06-10
JP2012121894A (ja) 2012-06-28
EP1778723A2 (en) 2007-05-02
CA2576519A1 (en) 2006-03-02
DK1778723T3 (da) 2012-12-03
AU2005277357B2 (en) 2011-08-04
CN101014617B (zh) 2011-03-30
CA2576519C (en) 2013-05-21
ES2395035T3 (es) 2013-02-07
EP2311871A3 (en) 2012-08-08
EP1778723B1 (en) 2012-11-14
WO2006023665A2 (en) 2006-03-02

Similar Documents

Publication Publication Date Title
ZA200701529B (en) Il-1 antagonist formulations
IL237756A0 (en) Antibody compositions
IL227215A (en) Vegf antagonists
EP1825866A4 (en) SOLID PREPARATION
GB0423565D0 (en) Formulation
EP1712218A4 (en) HAARFÄRBEZUBEREITUNG
GB0412530D0 (en) Formulation
GB0506035D0 (en) Improved formulation
ZA200606977B (en) Alkaloid formulations
GB0417226D0 (en) Formulations
IL179208A0 (en) Intereferon formulations
GB0417248D0 (en) Formulations
GB0409607D0 (en) Antagonist
GB0408112D0 (en) Improved formulation
GB0401114D0 (en) Formulation
GB0407958D0 (en) Formulation
GB0426142D0 (en) Formulation
GB0427248D0 (en) Novel formulations
GB0427244D0 (en) Novel formulations
GB0420817D0 (en) Novel formulations
GB0426292D0 (en) Novel formulations
GB0420818D0 (en) Novel formulations
GB0420820D0 (en) Novel formulations
GB0426294D0 (en) Novel formulations
GB0427245D0 (en) Novel formulations

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220822